Share Price and Basic Stock Data
Last Updated: January 7, 2026, 7:55 pm
| PEG Ratio | 738.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Achyut Healthcare Ltd operates within the pharmaceuticals sector and reported a current market price of ₹5.71, with a market capitalization of ₹135 Cr. The company’s revenue from operations has shown significant fluctuations in recent years. For instance, sales stood at ₹4.05 Cr in FY 2022, declining to ₹2.70 Cr in FY 2023, before rebounding to ₹6.14 Cr in FY 2024. The trailing twelve months (TTM) revenue reported is ₹6.56 Cr, indicating a recovery trend. Quarterly sales figures reflect this volatility, with a low of ₹0.81 Cr in Mar 2023 and a peak of ₹4.65 Cr in Mar 2024. This erratic performance suggests challenges in revenue consistency, yet the recent uptick in sales may signal a potential stabilization phase. The company’s operational performance, as indicated by the operating profit margin (OPM) of 2.66% in Sep 2025, aligns with industry standards, though it remains on the lower end compared to leading competitors.
Profitability and Efficiency Metrics
Achyut Healthcare’s profitability metrics reveal a mixed performance. The net profit reported for FY 2025 was ₹0.55 Cr, translating to a net profit margin of 17.97%, which is relatively robust compared to historical figures, such as 0.99% for FY 2022. However, the company’s return on equity (ROE) stands at a mere 1.77%, indicating limited profitability relative to shareholder equity. The interest coverage ratio, an impressive 3596.50x, suggests that the company is well-positioned to meet its financial obligations, as it has no borrowings. Operational efficiency is further illustrated by the cash conversion cycle of 40.81 days, which is within reasonable limits for the pharmaceutical sector. However, the company’s low operating profit (recorded at ₹0.02 Cr for FY 2024) indicates that while revenue generation is improving, controlling operational costs remains a significant challenge.
Balance Sheet Strength and Financial Ratios
The balance sheet of Achyut Healthcare reflects a strong position, with total assets reported at ₹34.02 Cr as of Sep 2025, and zero borrowings, indicating a debt-free status. The reserves have increased to ₹7.98 Cr from ₹5.18 Cr in FY 2023, showcasing a strengthening equity base. The company’s book value per share stood at ₹1.33 for FY 2025, which is significantly lower than the market price of ₹5.71, suggesting that the stock may be trading at a premium. The current ratio of 9.32x and quick ratio of 9.18x indicate excellent liquidity, suggesting that Achyut Healthcare can comfortably cover its short-term liabilities. However, the price-to-book value ratio of 2.45x suggests that investors may be paying a premium for the company’s equity, which could be a concern if profitability does not improve. Overall, the balance sheet indicates stability, yet profitability and operational efficiency need enhancement to justify the current market valuation.
Shareholding Pattern and Investor Confidence
As of Sep 2025, Achyut Healthcare’s shareholding pattern reveals that promoters hold 47.07% of the company, while public shareholders constitute 47.67%. Foreign institutional investors (FIIs) hold 5.26%, reflecting a cautious interest from external investors. The reduction in promoter holding from 66.18% in Mar 2022 to the current level indicates a gradual dilution, which may raise concerns regarding insider confidence in the company’s future performance. The number of shareholders has increased significantly from 245 in Mar 2022 to 565 in Sep 2025, suggesting growing public interest and confidence in the stock. However, the lack of significant participation from domestic institutional investors (DIIs) could indicate a perceived risk in the company’s growth trajectory. The increasing public ownership, alongside the low FII stake, suggests a mixed sentiment among investors, with potential for both growth and volatility.
Outlook, Risks, and Final Insight
Looking ahead, Achyut Healthcare faces a dual-edged scenario. On one hand, the recent revenue growth and strong liquidity position offer a foundation for potential expansion and operational improvement. The company may benefit from strategic initiatives to enhance profitability and operational efficiency. However, significant risks persist, including the inconsistent revenue trends and low ROE, which could hinder investor confidence. The rising costs of operations and the pharmaceutical industry’s competitive landscape pose additional challenges. The reliance on fluctuating sales and the need for improved cost management are critical focal points for future performance. If Achyut Healthcare can leverage its strong balance sheet and improve profitability metrics, it may stabilize its market position; conversely, failure to address these operational challenges could result in further volatility and diminished investor trust.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.92 Cr | 1,159.04 | 54.40 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.71 | 1.34 | 1.89 | 0.81 | 1.48 | 4.65 | 2.13 | 0.92 | 5.64 |
| Expenses | 2.56 | 1.53 | 1.87 | 1.10 | 1.45 | 4.66 | 2.21 | 1.04 | 5.49 |
| Operating Profit | 0.15 | -0.19 | 0.02 | -0.29 | 0.03 | -0.01 | -0.08 | -0.12 | 0.15 |
| OPM % | 5.54% | -14.18% | 1.06% | -35.80% | 2.03% | -0.22% | -3.76% | -13.04% | 2.66% |
| Other Income | 0.02 | 0.13 | 0.23 | 0.36 | 0.32 | 0.41 | 0.56 | 0.36 | 0.20 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.03 |
| Profit before tax | 0.17 | -0.07 | 0.25 | 0.07 | 0.35 | 0.40 | 0.47 | 0.24 | 0.32 |
| Tax % | 47.06% | -28.57% | 0.00% | 114.29% | 22.86% | 20.00% | 25.53% | 16.67% | 25.00% |
| Net Profit | 0.09 | -0.05 | 0.24 | -0.01 | 0.26 | 0.31 | 0.35 | 0.20 | 0.23 |
| EPS in Rs | 0.01 | -0.00 | 0.02 | -0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Last Updated: December 28, 2025, 9:33 am
Below is a detailed analysis of the quarterly data for Achyut Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 5.64 Cr.. The value appears strong and on an upward trend. It has increased from 0.92 Cr. (Mar 2025) to 5.64 Cr., marking an increase of 4.72 Cr..
- For Expenses, as of Sep 2025, the value is 5.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.04 Cr. (Mar 2025) to 5.49 Cr., marking an increase of 4.45 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from -0.12 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.27 Cr..
- For OPM %, as of Sep 2025, the value is 2.66%. The value appears strong and on an upward trend. It has increased from -13.04% (Mar 2025) to 2.66%, marking an increase of 15.70%.
- For Other Income, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.36 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.16 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.32 Cr.. The value appears strong and on an upward trend. It has increased from 0.24 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.08 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.67% (Mar 2025) to 25.00%, marking an increase of 8.33%.
- For Net Profit, as of Sep 2025, the value is 0.23 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 0.23 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.01. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:20 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.67 | 0.33 | 0.27 | 4.05 | 2.70 | 6.14 | 3.05 | 6.56 |
| Expenses | 0.66 | 0.32 | 0.26 | 4.08 | 2.97 | 6.12 | 3.25 | 6.53 |
| Operating Profit | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 | 0.03 |
| OPM % | 1.49% | 3.03% | 3.70% | -0.74% | -10.00% | 0.33% | -6.56% | 0.46% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.14 | 0.59 | 0.73 | 0.92 | 0.56 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 |
| Profit before tax | 0.01 | 0.02 | 0.01 | 0.10 | 0.31 | 0.74 | 0.70 | 0.56 |
| Tax % | 300.00% | 0.00% | 0.00% | 60.00% | 25.81% | 32.43% | 22.86% | |
| Net Profit | -0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.50 | 0.55 | 0.43 |
| EPS in Rs | -0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 0.00% | 300.00% | 475.00% | 117.39% | 10.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 300.00% | 175.00% | -357.61% | -107.39% |
Achyut Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | -9% |
| TTM: | -50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 123% |
| 3 Years: | 140% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 88% |
| 1 Year: | 44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 10, 2025, 3:43 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 6.74 | 9.35 | 16.83 | 23.56 | 23.56 |
| Reserves | -0.05 | -0.04 | 0.00 | 2.34 | 5.18 | 13.93 | 7.74 | 7.98 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.19 | 1.29 | 2.48 |
| Total Liabilities | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 34.02 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 | 0.03 | 0.26 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.49 | 9.16 | 18.19 | 24.38 |
| Investments | 0.00 | 0.00 | 0.00 | 1.70 | 1.30 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.24 | 0.27 | 0.50 | 8.21 | 10.50 | 21.73 | 14.37 | 9.38 |
| Total Assets | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 34.02 |
Below is a detailed analysis of the balance sheet data for Achyut Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 23.56 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.56 Cr..
- For Reserves, as of Sep 2025, the value is 7.98 Cr.. The value appears strong and on an upward trend. It has increased from 7.74 Cr. (Mar 2025) to 7.98 Cr., marking an increase of 0.24 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.48 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.29 Cr. (Mar 2025) to 2.48 Cr., marking an increase of 1.19 Cr..
- For Total Liabilities, as of Sep 2025, the value is 34.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.59 Cr. (Mar 2025) to 34.02 Cr., marking an increase of 1.43 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.26 Cr., marking an increase of 0.23 Cr..
- For CWIP, as of Sep 2025, the value is 24.38 Cr.. The value appears strong and on an upward trend. It has increased from 18.19 Cr. (Mar 2025) to 24.38 Cr., marking an increase of 6.19 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 9.38 Cr.. The value appears to be declining and may need further review. It has decreased from 14.37 Cr. (Mar 2025) to 9.38 Cr., marking a decrease of 4.99 Cr..
- For Total Assets, as of Sep 2025, the value is 34.02 Cr.. The value appears strong and on an upward trend. It has increased from 32.59 Cr. (Mar 2025) to 34.02 Cr., marking an increase of 1.43 Cr..
Notably, the Reserves (7.98 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 54.48 | 188.03 | 378.52 | 18.02 | 36.50 | 24.37 | 160.36 |
| Inventory Days | 0.00 | 0.00 | 158.70 | 14.29 | 59.59 | 3.96 | 24.16 |
| Days Payable | 380.87 | 41.78 | 55.87 | 12.54 | 143.71 | ||
| Cash Conversion Cycle | 54.48 | 188.03 | 156.34 | -9.46 | 40.22 | 15.79 | 40.81 |
| Working Capital Days | 76.27 | 210.15 | 216.30 | 603.83 | 1,257.22 | 1,242.43 | 1,169.20 |
| ROCE % | 9.76% | 4.35% | 2.14% | 2.63% | 3.27% | 2.26% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Diluted EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Cash EPS (Rs.) | 0.02 | 0.34 | 0.25 | 0.06 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Revenue From Operations / Share (Rs.) | 0.12 | 3.65 | 2.88 | 6.01 | 10.91 |
| PBDIT / Share (Rs.) | 0.03 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBIT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.14 | 0.40 |
| Net Profit / Share (Rs.) | 0.02 | 0.34 | 0.24 | 0.05 | 0.29 |
| PBDIT Margin (%) | 23.60 | 12.24 | 11.78 | 2.62 | 3.85 |
| PBIT Margin (%) | 23.09 | 12.11 | 11.54 | 2.49 | 3.85 |
| PBT Margin (%) | 23.08 | 12.07 | 11.48 | 2.48 | 3.74 |
| Net Profit Margin (%) | 17.97 | 9.34 | 8.57 | 0.99 | 2.71 |
| Return on Networth / Equity (%) | 1.74 | 1.86 | 1.59 | 0.44 | 3.41 |
| Return on Capital Employeed (%) | 2.24 | 2.41 | 2.14 | 1.11 | 4.83 |
| Return On Assets (%) | 1.68 | 1.85 | 1.50 | 0.40 | 1.57 |
| Asset Turnover Ratio (%) | 0.09 | 0.26 | 0.21 | 0.77 | 0.73 |
| Current Ratio (X) | 9.32 | 106.66 | 12.68 | 9.46 | 1.82 |
| Quick Ratio (X) | 9.18 | 106.38 | 12.29 | 9.31 | 1.44 |
| Inventory Turnover Ratio (X) | 25.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3596.50 | 375.85 | 186.88 | 169.54 | 35.00 |
| Interest Coverage Ratio (Post Tax) (X) | 2739.50 | 287.60 | 137.00 | 65.14 | 25.67 |
| Enterprise Value (Cr.) | 75.79 | 87.10 | 50.86 | 13.59 | 0.00 |
| EV / Net Operating Revenue (X) | 24.87 | 14.19 | 18.87 | 3.36 | 0.00 |
| EV / EBITDA (X) | 105.37 | 115.87 | 160.10 | 127.69 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 25.20 | 14.25 | 18.96 | 3.42 | 0.00 |
| Price / BV (X) | 2.45 | 2.84 | 3.52 | 1.52 | 0.00 |
| Price / Net Operating Revenue (X) | 25.21 | 14.26 | 18.96 | 3.42 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Achyut Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.12. It has decreased from 3.65 (Mar 24) to 0.12, marking a decrease of 3.53.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.44 (Mar 24) to 0.03, marking a decrease of 0.41.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For PBDIT Margin (%), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 12.24 (Mar 24) to 23.60, marking an increase of 11.36.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 12.11 (Mar 24) to 23.09, marking an increase of 10.98.
- For PBT Margin (%), as of Mar 25, the value is 23.08. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 23.08, marking an increase of 11.01.
- For Net Profit Margin (%), as of Mar 25, the value is 17.97. This value exceeds the healthy maximum of 10. It has increased from 9.34 (Mar 24) to 17.97, marking an increase of 8.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.74. This value is below the healthy minimum of 15. It has decreased from 1.86 (Mar 24) to 1.74, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.24. This value is below the healthy minimum of 10. It has decreased from 2.41 (Mar 24) to 2.24, marking a decrease of 0.17.
- For Return On Assets (%), as of Mar 25, the value is 1.68. This value is below the healthy minimum of 5. It has decreased from 1.85 (Mar 24) to 1.68, marking a decrease of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.09. It has decreased from 0.26 (Mar 24) to 0.09, marking a decrease of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 9.32. This value exceeds the healthy maximum of 3. It has decreased from 106.66 (Mar 24) to 9.32, marking a decrease of 97.34.
- For Quick Ratio (X), as of Mar 25, the value is 9.18. This value exceeds the healthy maximum of 2. It has decreased from 106.38 (Mar 24) to 9.18, marking a decrease of 97.20.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 25.09. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 25.09, marking an increase of 25.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3,596.50. This value is within the healthy range. It has increased from 375.85 (Mar 24) to 3,596.50, marking an increase of 3,220.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2,739.50. This value is within the healthy range. It has increased from 287.60 (Mar 24) to 2,739.50, marking an increase of 2,451.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 75.79. It has decreased from 87.10 (Mar 24) to 75.79, marking a decrease of 11.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has increased from 14.19 (Mar 24) to 24.87, marking an increase of 10.68.
- For EV / EBITDA (X), as of Mar 25, the value is 105.37. This value exceeds the healthy maximum of 15. It has decreased from 115.87 (Mar 24) to 105.37, marking a decrease of 10.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 25.20. This value exceeds the healthy maximum of 3. It has increased from 14.25 (Mar 24) to 25.20, marking an increase of 10.95.
- For Price / BV (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has decreased from 2.84 (Mar 24) to 2.45, marking a decrease of 0.39.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 25.21. This value exceeds the healthy maximum of 3. It has increased from 14.26 (Mar 24) to 25.21, marking an increase of 10.95.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Achyut Healthcare Ltd:
- Net Profit Margin: 17.97%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.74% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2739.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 9.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 293 (Industry average Stock P/E: 54.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.97%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 610, Colonade, B/H Iscon Temple, Opposite Iscon, BRTS Bus Stand, Ahmedabad Gujarat 380058 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra C Raycha | Chairman & Non-Exe.Director |
| Mr. Jigen J Modi | Managing Director |
| Ms. Amisha J Modi | Executive Director |
| Mr. Akshit Raycha | Non Executive Director |
| Mr. Rutvik S Thakkar | Independent Director |
| Mrs. Sonu L Jain | Independent Director |
| Mr. Paragkumar S Dave | Independent Director |
| Mr. Rajesh C Sutaria | Independent Director |
FAQ
What is the intrinsic value of Achyut Healthcare Ltd?
Achyut Healthcare Ltd's intrinsic value (as of 07 January 2026) is ₹5.67 which is 6.18% higher the current market price of ₹5.34, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹126 Cr. market cap, FY2025-2026 high/low of ₹6.57/2.82, reserves of ₹7.98 Cr, and liabilities of ₹34.02 Cr.
What is the Market Cap of Achyut Healthcare Ltd?
The Market Cap of Achyut Healthcare Ltd is 126 Cr..
What is the current Stock Price of Achyut Healthcare Ltd as on 07 January 2026?
The current stock price of Achyut Healthcare Ltd as on 07 January 2026 is ₹5.34.
What is the High / Low of Achyut Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Achyut Healthcare Ltd stocks is ₹6.57/2.82.
What is the Stock P/E of Achyut Healthcare Ltd?
The Stock P/E of Achyut Healthcare Ltd is 293.
What is the Book Value of Achyut Healthcare Ltd?
The Book Value of Achyut Healthcare Ltd is 1.34.
What is the Dividend Yield of Achyut Healthcare Ltd?
The Dividend Yield of Achyut Healthcare Ltd is 0.00 %.
What is the ROCE of Achyut Healthcare Ltd?
The ROCE of Achyut Healthcare Ltd is 2.26 %.
What is the ROE of Achyut Healthcare Ltd?
The ROE of Achyut Healthcare Ltd is 1.77 %.
What is the Face Value of Achyut Healthcare Ltd?
The Face Value of Achyut Healthcare Ltd is 1.00.